JP2023529640A5 - - Google Patents
Info
- Publication number
- JP2023529640A5 JP2023529640A5 JP2022574600A JP2022574600A JP2023529640A5 JP 2023529640 A5 JP2023529640 A5 JP 2023529640A5 JP 2022574600 A JP2022574600 A JP 2022574600A JP 2022574600 A JP2022574600 A JP 2022574600A JP 2023529640 A5 JP2023529640 A5 JP 2023529640A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate according
- group
- targeting agent
- cancer
- dendrimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901833A AU2020901833A0 (en) | 2020-06-03 | Therapeutic conjugates | |
| AU2020901833 | 2020-06-03 | ||
| PCT/AU2021/050554 WO2021243415A1 (en) | 2020-06-03 | 2021-06-03 | Therapeutic conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529640A JP2023529640A (ja) | 2023-07-11 |
| JP2023529640A5 true JP2023529640A5 (https=) | 2024-06-10 |
Family
ID=78831413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574600A Pending JP2023529640A (ja) | 2020-06-03 | 2021-06-03 | 治療用コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240293588A1 (https=) |
| JP (1) | JP2023529640A (https=) |
| KR (1) | KR20230065935A (https=) |
| CN (1) | CN115989039A (https=) |
| AU (1) | AU2021284918A1 (https=) |
| CA (1) | CA3180877A1 (https=) |
| WO (1) | WO2021243415A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| WO2024007034A2 (en) * | 2022-07-01 | 2024-01-04 | The Johns Hopkins University | Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and other cancers in the brain |
| WO2024168199A1 (en) * | 2023-02-09 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| WO2026046228A1 (zh) * | 2024-08-27 | 2026-03-05 | 苏州拓界医药有限公司 | 树枝状聚合物偶联物及其制备方法 |
| CN120025408B (zh) * | 2025-04-23 | 2025-08-01 | 湖南中晟全肽生物科技股份有限公司 | 一种靶向fgfr2的多肽核素配体、探针及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5989294B2 (ja) * | 2006-01-20 | 2016-09-07 | スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | 修飾高分子 |
| WO2009127691A1 (en) * | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| CA2770980A1 (en) * | 2009-07-15 | 2011-01-20 | Roger Y. Tsien | Peptides whose uptake in cells is controllable |
| IN2014DN00101A (https=) * | 2011-06-06 | 2015-05-15 | Starpharma Pty Ltd | |
| US20160106856A1 (en) * | 2012-08-14 | 2016-04-21 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| US9642916B2 (en) * | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
| US10550201B2 (en) * | 2013-03-13 | 2020-02-04 | Bioventures, Llc | Antibody-nanoparticle conjugates for the treatment of drug abuse |
| US10898594B2 (en) * | 2015-10-27 | 2021-01-26 | The Johns Hopkins University | PAMAM dendrimer based CEST imaging agents and uses thereof |
| JP7541978B2 (ja) * | 2018-11-29 | 2024-08-29 | スターファーマ ピーティーワイ エルティーディー | 治療および画像化のためのデンドリマー |
-
2021
- 2021-06-03 KR KR1020227046150A patent/KR20230065935A/ko active Pending
- 2021-06-03 AU AU2021284918A patent/AU2021284918A1/en active Pending
- 2021-06-03 WO PCT/AU2021/050554 patent/WO2021243415A1/en not_active Ceased
- 2021-06-03 US US17/928,306 patent/US20240293588A1/en active Pending
- 2021-06-03 JP JP2022574600A patent/JP2023529640A/ja active Pending
- 2021-06-03 CA CA3180877A patent/CA3180877A1/en active Pending
- 2021-06-03 CN CN202180049571.2A patent/CN115989039A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529640A5 (https=) | ||
| JP5084267B2 (ja) | 多特異性抗体との使用のための治療および診断用コンジュゲート | |
| US20240216525A1 (en) | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties | |
| JP6677489B2 (ja) | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 | |
| JP2022525704A5 (https=) | ||
| JP2008546792A5 (https=) | ||
| US11801307B2 (en) | Antibody-polymer-drug conjugates | |
| JP2018127469A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2022547434A5 (https=) | ||
| US20240293588A1 (en) | Therapeutic conjugates | |
| CN109963620A (zh) | 细胞靶向缀合物 | |
| JP2006507803A5 (https=) | ||
| JP2008515889A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2022513630A5 (https=) | ||
| JP2024501894A5 (https=) | ||
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP2019524640A5 (https=) | ||
| JP2016509586A5 (https=) | ||
| JP2011505371A5 (https=) | ||
| JP2025535447A5 (https=) | ||
| Liu et al. | Utility of 131I-HLX58-Der for the precision treatment: evaluation of a preclinical radio-antibody-drug-conjugate approach in mouse models | |
| Zalutsky et al. | Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent |